Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Empagliflozin vs Metformin: they're closely matched on evidence (4.5 vs 4/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Empagliflozin and Metformin are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Off-label use mirrors approved dosing (10–25 mg once daily in the morning) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (empagliflozin)
Off-label longevity use mirrors diabetes dosing (commonly 500–1500 mg/day of extended-release with meals) under a clinician. Not an approved longevity regimen, and unnecessary in well-controlled non-diabetics without a clear rationale.
with-meals
Extended-release tablet
Months to years
Months to years
Weeks to months
Throughout use
Weeks
Years
Weeks of training
Days (GI) to years (B12)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine (2015) · Rct · n=7020
EMPA-REG OUTCOME randomized trial in high-CV-risk type-2 diabetics
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation (2018) · Rct
Randomized evidence of empagliflozin benefit in established cardiovascular disease
Empagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2023) · Rct
EMPA-KIDNEY randomized trial in a broad chronic-kidney-disease population
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet (London, England) (1998) · Rct · n=753
UKPDS 34 randomized trial of metformin in overweight type-2 diabetics
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Ageing research reviews (2017) · Meta analysis
Systematic review/meta-analysis of metformin and age-related outcomes
Metformin as a Tool to Target Aging.
Cell metabolism (2016) · Review
Review of metformin's aging-relevant mechanisms (AMPK, insulin/IGF-1, inflammation)
Both Empagliflozin and Metformin are closely matched — the best choice depends on your specific health goals.
For manage blood sugar, Metformin has a higher relevance score (72 vs 62).
No known interactions between Empagliflozin and Metformin have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.